Olanzapine and pancreatitis

Hagger, R; Brown, Cedric; Hurley, Paul R.

doi:10.1192/bjp.177.6.567

Cited by 24 publications

(14 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute pancreatitis associated with clozapine was recognized when it was first introduced [4, 5]. Since 2000, there have been four cases of olanzapine associated pancreatitis reported in the literature [6, 7, 8]. The interval between initiation of olanzapine and onset of pancreatitis can be long, and has been reported to range from a few weeks to over 18 months [6, 7, 8], consistent with our observations.…”

Section: Discussionsupporting

confidence: 87%

“…Clozapine was initially linked to acute pancreatitis in 1992 [4, 5], and there has been concern that newer atypical antipsychotic agents, including olanzapine, could potentially also cause acute pancreatitis. At least three individual case reports have reported an association between olanzapine and acute pancreatitis [6, 7, 8], and a MedWatch surveillance system review [3] has also evaluated the connection. We report a series of three patients presenting with clinical and/or laboratory evidence of acute pancreatitis while being treated with olanzapine.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pancreatitis following Olanzapine Therapy: A Report of Three Cases

Kerr¹,

Jonnalagadda²,

Prakash³

et al. 2007

Case Rep Gastroenterol

View full text Add to dashboard Cite

Context: Atypical antipsychotic agents (clozapine, olanzapine) have been linked to metabolic effects and acute pancreatitis. Case Report: We reviewed the inpatient and outpatient records of three patients who developed acute pancreatitis while being treated with olanzapine. The mean age of the patients was 37.7 years (range 18–54 years, 2 female, 1 male). No alternative cause of acute pancreatitis was found in two of the three patients. In the remaining patient, olanzapine may have contributed to acute pancreatitis in the setting of hypertriglyceridemia. Olanzapine was discontinued in all instances. Over a mean follow-up of 14 months, one patient has had a relapsing course, but the remaining two patients have been symptom free without recurrence of acute pancreatitis. Conclusions: Our case series adds further support to the potential link between olanzapine use and acute pancreatitis. Close monitoring of metabolic parameters is suggested in patients treated with olanzapine. Alternative antipsychotic agents should be considered in patients at high risk for pancreatitis.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Pancreatitis following Olanzapine Therapy: A Report of Three Cases

Kerr¹,

Jonnalagadda²,

Prakash³

et al. 2007

Case Rep Gastroenterol

View full text Add to dashboard Cite

show abstract

“…1 Some cases of olanzapine-induced pancreatitis have been published since 2000. 17,18 In this study, the olanzapine-induced decrease in insulin secretion might be related to direct damage of pancreatic b cells. In a placebocontrolled study of olanzapine and risperidone in dogs, olanzapine resulted in marked hepatic insulin resistance and impairment in the compensatory up-regulation of b-cell sensitivity to glucose.…”

Section: Discussionmentioning

confidence: 69%

The Early Effect of Olanzapine and Risperidone on Insulin Secretion in Atypical-naïve Schizophrenic Patients

Chiu¹,

Chen²,

Liu³

et al. 2006

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Recently, increasing attention has been drawn to the potential diabetogenic effect of atypical antipsychotics. The goal of this prospective study is to evaluate the early effect of olanzapine and risperidone treatment on pancreatic beta-cell function in atypical-naive schizophrenic patients. Twenty-six subjects were assigned randomly to therapy with olanzapine or risperidone for 14 days. The metabolic parameters were quantitatively assessed by using the intravenous glucose tolerance test. The levels of fasting glucose, fasting insulin, lipid profiles, and leptin were also assessed. There were no significant within-group changes in weight or body mass index for both groups after 2 weeks of treatment. The levels of fasting glucose, fasting insulin, cholesterol, or leptin did not change in both groups. The triglyceride level significantly increased in olanzapine group. Glucose disappearance rate and insulin sensitivity did not change in both groups. Insulin secretion significantly decreased in olanzapine group. After 2 weeks of olanzapine treatment, schizophrenic patients decreased insulin secretory response to a hyperglycemic challenge. The results of this study support the hypothesis that olanzapine might directly impair pancreatic beta-cell function.

show abstract

“…A PubMed search of olanzapine induced pancreatitis revealed 11 case reports from 2000 to the current date [6][7][8][9][10][11][12][13] but no case reports in Australasia. There are no reports on doxepin-related pancreatitis from 1966 to the current date.…”

Section: Discussionmentioning

confidence: 99%

“…Interestingly, the patient described in our report had normal triglyceride serum levels. A 2000 correspondence article [10] and a subsequent case report [6] outline three cases of pancreatitis associated with significant alcohol intake, well beyond the national recommended guidelines. The authors proposed that olanzapine should be used in caution with patients who drink alcohol on a regular basis or who have a history of previous pancreatitis.…”

Section: Discussionmentioning

confidence: 99%

Case report: Olanzapine-induced acute pancreatitis and new diabetes mellitus

Monasterio¹,

Bhalla²,

McKean³

2012

OJPsych

View full text Add to dashboard Cite

The aim of this case study is to review the literature and report the first published case of olanzapine-induced acute pancreatitis in New Zealand. A case report of acute pancreatitis with new onset diabetes mellitus secondary to olanzapine in a 42-year-old male, in the absence of medical risk factors is reported. Eleven previous case reports of olanzapine induced acute-pancreatitis were identified in the literature. A 42-year-old male was diagnosed with acute pancreatitis and new diabetes mellitus induced by olanzapine. Although rare, pancreatitis is associated with use of some atypical antipsychotic medications. It is important for prescribers to be aware of this potentially fatal side effect. In addition to this, we are highlighting the well documented evidence of metabolic disruption associated with olanzapine.

show abstract

Olanzapine and pancreatitis

Abstract: Spinning on its axes: Spinning on its axes: DSM and the social construction of psychiatric diagnosis. DSM and the social construction of psychiatric diagnosis.

Cited by 24 publications

References 1 publication

Pancreatitis following Olanzapine Therapy: A Report of Three Cases

Pancreatitis following Olanzapine Therapy: A Report of Three Cases

The Early Effect of Olanzapine and Risperidone on Insulin Secretion in Atypical-naïve Schizophrenic Patients

Case report: Olanzapine-induced acute pancreatitis and new diabetes mellitus

Contact Info

Product

Resources

About